TLDR:
Brandon Capital, an Australian VC firm, closes a new AU$270M fund to support life sciences startups in Australia, New Zealand, and internationally. The fund will focus on expanding into the U.K., Europe, and the U.S.
Key Points:
- Brandon Capital announces the first close of its sixth fund for AU$270 million.
- The fund aims to seed new life sciences startups in Australia and New Zealand and expand internationally.
Australian VC firm Brandon Capital recently announced the first close of its sixth fund for AU$270 million during the 2024 Biotechnology Innovation Organization International Convention in San Diego. The fund, known as Fund VI, will be used to support and seed new life sciences startups in Australia and New Zealand. In addition, Brandon Capital plans to use the fund to expand its presence in international markets, with a particular focus on the U.K., Europe, and the U.S.
The announcement was made at a key event in the biotechnology industry, signaling Brandon Capital’s commitment to fostering innovation and growth in the life sciences sector. With the new fund, the firm aims to provide crucial funding and support to early-stage companies, helping them to bring new treatments and technologies to market.
